science1 distinct publisher
A RAS inhibitor wins FDA approval in metastatic pancreatic cancer at $39,800 a month
Revolution Medicines' daraxonrasib nearly doubled median overall survival in previously treated patients. Investors sat still anyway, because the unresolved variable is now what payers will absorb.
Publishers:genengnews.com
Reality
- Evidence70
- Adoption34
- Hype gap+16
- Incentives72